Citeline Podcasts

→ WHAT IT COVERS Generics Bulletin editors report from two February 2026 industry conferences — AAM's Access meeting in Miami and Medicines for Europe's regulatory conference in Amsterdam — covering biosimilar streamlining, EU pharma legislation reform, tariffs, and PBM accountability across global off-patent markets. → KEY INSIGHTS - **EU Pharma Legislation Timeline:** The EU's first regulatory framework overhaul in 20 years enters formal adoption in Q2 2026, with provisions taking effect...

→ WHAT IT COVERS Probiotics expert David Pineda Ereño outlines how consumer health companies can navigate Europe's fragmented regulatory claims environment, covering market entry strategies across 27 EU member states, umbrella brand tactics, emerging probiotic research in weight management and fertility, and the commercial potential of postbiotics as a newer, more stable product category.

→ WHAT IT COVERS Five biotech and pharma developments from the week of March 13, 2026: Roche's Giadestrant phase three failure, BioNTech's founders departing, Ipsen withdrawing Tazverik, Bayer's mixed earnings, and UCB's Bimzelx beating Skyrizi in psoriatic arthritis. → KEY INSIGHTS - **Roche Pipeline Risk:** Giadestrant failed the PERSEVERA trial's primary endpoint in first-line ER-positive, HER2-negative advanced breast cancer despite enrolling 992 patients.

→ WHAT IT COVERS Vinay Prasad's departure from CBER leadership creates a second senior FDA vacancy in under a year, while analysis of the Commissioner's National Priority Review Voucher program reveals its fastest approvals rely heavily on the pre-existing Real-Time Oncology Review framework rather than the CNPV mechanism itself. → KEY INSIGHTS - **CBER Leadership Succession:** With Prasad departing in late April 2026, McCary has roughly six weeks to name a replacement — too short for...

→ WHAT IT COVERS Onchilles Pharma cofounders Court Turner and Lev Becker explain how their lead compound N17350 exploits neutrophil elastase and elevated histone H1 to selectively kill cancer cells while activating immunity, with $41M raised, GMP manufacturing complete, and first-in-human trials launching across solid tumors in Australia and the US. → KEY INSIGHTS - **Selective cytotoxicity via histone H1:** N17350 targets a universal cancer vulnerability — elevated histone H1 — present across...

→ WHAT IT COVERS Five pharma business developments for the week ending March 6, 2026: MFN pricing stalls European launches, FDA vaccine leadership criticism, AI investment pressure on CRDMOs, neuroscience funding revival signals, and UCB's $1.1B China biotech deal. → KEY INSIGHTS - **MFN Pricing Risk:** Smaller biotech firms like Insmed are halting European launches and pausing ex-US outlicensing deals until MFN policy clarity emerges.

→ WHAT IT COVERS Two former senior FDA executives from Canal Row Advisors — Doug Stern and Michael Rogers — analyze the deteriorating state of FDA facility inspections, covering staffing attrition, the generalist inspector shift, foreign inspection logistics, OAI classification consequences, and the agency's likely pivot toward third-party and signal-based oversight models.

→ WHAT IT COVERS Bio David Pineda Ere, managing director of DP International Consulting, breaks down Europe's fragmented probiotic regulatory landscape, explaining why the EU Commission classifies "probiotic" as an unauthorized health claim, how member states are diverging, and what Codex Alimentarius reform could mean for the industry. → KEY INSIGHTS - **EU Health Claim Barrier:** The term "probiotic" is blocked from product labels across much of the EU because the FAO/WHO definition...

→ WHAT IT COVERS Scrip's weekly briefing covers five biopharma developments: Zealand's GLP-1 durability argument, MSD's AI-doubled discovery pipeline, CAR-T advances at Penn Medicine, a 400%-plus rebound in 2025 deal values, and a halved US IPO market. → KEY INSIGHTS - **GLP-1 Retention Strategy:** Zealand CEO Adam Steensburg argues the obesity market will be won on treatment persistence, not maximum weight loss.

→ WHAT IT COVERS Recorded February 27, 2026, Drug Fix covers the Association for Accessible Medicines annual conference with Dave Wallace and Matt Hobbs reporting on generics industry momentum, biosimilar regulatory streamlining, US manufacturing reshoring pressures, and FDA Commissioner Martin McCarry's controversial compassionate use comments raising political interference concerns.

→ WHAT IT COVERS Affibody CEO David Baker explains how the Stockholm-based biotech's engineered proteins — one-twentieth the size of monoclonal antibodies — are designed to expand the radioligand therapy target space beyond the handful of peptide-accessible targets like PSMA and SSTR that currently dominate the entire RLT pipeline. → KEY INSIGHTS - **Radioligand target bottleneck:** The entire current RLT pipeline is concentrated around just four targets — SSTR, PSMA, FAPI, and DLL3 — all...